Background A meta-analysis of randomised trials in relapsing-remitting multiple sclerosis
published in 2009 showed a quantitative relation between the treatment effects detected on …

The Canadian Multiple Sclerosis Working Group (CMSWG) developed practical
recommendations in 2004 to assist clinicians in optimizing the use of disease-modifying …

Whether B cells serve as antigen-presenting cells (APCs) for activation of pathogenic T cells
in the multiple sclerosis model experimental autoimmune encephalomyelitis (EAE) is …

Objective To investigate the efficacy and safety of ocrelizumab in patients with class III/IV
lupus nephritis (LN). Methods Patients were randomized 1: 1: 1 to receive placebo, 400 mg …

The association between lymphopenia and autoimmunity is recognized, but the underlying
mechanisms are poorly understood and have not been studied systematically in humans …

We have entered a golden era in multiple sclerosis (MS) research. Two decades ago, our
understanding of the disease was largely descriptive and there were no approved therapies …

Recent years have substantially broadened our view on the pathogenesis of multiple
sclerosis (MS). While earlier concepts focused predominantly on T lymphocytes as the key …

Epidemiological and clinical studies have shown that environmental factors such as
infections, smoking and vitamin D are associated with the risk of developing multiple …

In recent years, multiple sclerosis (MS) research has progressed on several fronts,
prompting numerous clinical trials, primarily for immunotherapeutics. Although several new …

Several innovative disease-modifying treatments (DMTs) for relapsing-remitting multiple
sclerosis have been licensed recently or are in late-stage development. The molecular …